Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 80, Issue 2 , Pages 131-136 , February 2009

Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis,

  • L. Shinto

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • Corresponding Author InformationCorresponding author. Tel.: +15034945035; fax: +15034188373.
    • L. Shinto and G. Marracci contributed equally to this work.
    • ,
  • G. Marracci

      Affiliations

    • Department of Veterans Affairs Medical Center, Portland, OR, USA
    • L. Shinto and G. Marracci contributed equally to this work.
    • ,
  • S. Baldauf-Wagner

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • ,
  • A. Strehlow

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • Department of Veterans Affairs Medical Center, Portland, OR, USA
    • ,
  • V. Yadav

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • Department of Veterans Affairs Medical Center, Portland, OR, USA
    • ,
  • L. Stuber

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • ,
  • D. Bourdette

      Affiliations

    • Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
    • Department of Veterans Affairs Medical Center, Portland, OR, USA

Received 15 May 2007 ,Revised 25 November 2008 ,Accepted 15 December 2008.

References 

  1. Hafler DA, Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 1995;144:75–107
  2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992;10:153–187
  3. Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv. Neurol. 2006;98:27–45
  4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results. Neurology. 1993;43:655–661
  5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–1276
  6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann. Neurol. 1996;39(3):285–294
  7. PRISMS Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–1504
  8. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann. Neurol. 2006;60(2):236–242
  9. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 2006;59(5):748–754
  10. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult. Scler. 1998;4(6):487–489
  11. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult. Scler. 2008;14(2):212–218
  12. Calder PC. Dietary modification of inflammation with lipids. Proc. Nutr. Soc. 2002;61(3):345–358
  13. Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications. Nutrition. 2000;16(11–12):1116–1118
  14. Cleland LG, James MJ. Fish oil and rheumatoid arthritis: antiinflammatory and collateral health benefits. J. Rheumatol. 2000;27(10):2305–2307
  15. Gallai V, Sarchielli P, Trequattrini A, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J. Neuroimmunol. 1995;56(2):143–153
  16. Weinstock-Guttman B, Bayer M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot. Essent. Fatty Acids. 2005;73(5):397–404
  17. Curtis CL, Rees SG, Little CB, et al. Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. 2002;46(6):1544–1553
  18. Harris MA, Hansen RA, Vidsudhiphan P, et al. Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukot. Essent. Fatty Acids. 2001;65(1):23–29
  19. McCabe AJ, Wallace J, Gilmore WS, et al. The effect of eicosapentanoic acid on matrix metalloproteinase gene expression. Lipids. 1999;34(Suppl.):S217–S218
  20. Liuzzi GM, Latronico T, Rossano R, et al. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells—implications for complementary multiple sclerosis treatment. Neurochem. Res. 2007;32(12):2184–2193
  21. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 2001;36(2–3):249–257
  22. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53(7):1397–1401
  23. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology. 1999;53(7):1402–1408
  24. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 1999;122(Part 2):191–197
  25. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126(Part 12):2738–2749
  26. Dressel A, Mirowska-Guzel D, Gerlach C, et al. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta. Neurol. Scand. 2007;116(3):164–168
  27. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996;40(6):853–863
  28. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996;40(6):846–852
  29. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001;50(1):121–127
  30. Fischer JS, LaRocca NG, Miller DM, et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult. Scler. 1999;5(4):251–259
  31. Ruyle M, Connor WE, Anderson GJ, Lowensohn RI. Placental transfer of essential fatty acids in humans: venous-arterial difference for docosahexaenoic acid in fetal umbilical erythrocytes. Proc. Natl. Acad. Sci. USA. 1990;87(20):7902–7906
  32. Anderson GJ, Connor WE, Corliss JD, et al. Rapid modulation of the n-3 docosahexaenoic acid levels in the brain and retina of the newly hatched chick. J. Lipid Res. 1989;30(3):433–441
  33. Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  34. Avolio C, Giuliani F, Liuzzi GM, et al. Adhesion molecules and matrix metalloproteinases in multiple sclerosis: effects induced by interferon-beta. Brain Res. Bull. 2003;61(3):357–364
  35. Lichtinghagen R, Seifert T, Kracke A, et al. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J. Neuroimmunol. 1999;99(1):19–26
  36. Ozenci V, Rinaldi L, Teleshova D, et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 1999;12(4):297–303
  37. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68(24, Suppl. 4):S8–S11
  38. St-Pierre Y, Van Themsche C, Esteve PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr. Drug. Targets Inflamm. Allergy. 2003;2(3):206–215
  39. Zhao G, Etherton TD, Martin KR, et al. Anti-inflammatory effects of polyunsaturated fatty acid in THP-1 cells. Biochem. Biophys. Res. Commun. 2005;336(3):909–917
  40. Chen W, Esselman WJ, Jump DB, et al. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 2005;46(11):4342–4347
  41. Zhao Y, Chen LH. Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. J. Nutr. Biochem. 2005;16(2):78–84
  42. Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 2006;108(2):124–128
  43. Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult. Scler. 2005;11(4):441–446
  44. Karabudak R, Kurne A, Guc D, et al. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J. Neurol. 2004;251(3):279–283
  45. Waubant E, Goodkin D, Bostrom A, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology. 2003;60(1):52–57
  46. Waubant E, Gee L, Miller K, et al. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 2001;21(3):181–185
  47. Marsen TA, Pollok M, Oette K, Baldamus CA. Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations. Prostaglandins Leukot. Essent. Fatty Acids. 1992;46(3):191–196
  48. Wu N, Minden SL, Hoaglin DC. Quality of life in people with multiple sclerosis: data from the Sonya Slifka longitudinal multiple sclerosis study. J. Health Hum. Serv. Admin. 2007;30(3):233–267
  49. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult. Scler. 2003;9(1):63–72
  50. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545–552

☆ None of the authors have anything to disclose.

☆☆ This research was support by the National Institutes of Health P50 AT00066-01, the Department of Veterans Affairs, and the Nancy Davis Center Without Walls.

PII: S0952-3278(08)00189-0

doi: 10.1016/j.plefa.2008.12.001

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 80, Issue 2 , Pages 131-136 , February 2009

Article Tools

* Image Usage & Resolution